We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
HUTCHMED
A sharper focus on the path to profitabilityHUTCHMED
Fruquintinib should continue to bear fruitArecor Therapeutics
Specialty Hospital products formulation collaborationFutura Medical
On the cusp of MED3000 commercialisationScancell
FY22 results highlight clinical and corporate progressAllergy Therapeutics
Manufacturing pause takes it toll on revenuesScancell
Optimum partner secured for first antibody dealAvacta
Diagnostics M&A-led growth strategy is ready to LaunchArecor Therapeutics
AT247 Phase I pump data confirms promising profileRedx Pharma
New data draws attention to promising fibrosis assets